Dietary Glycine Prevents FOLFOX Chemotherapy-Induced Heart Injury: A Colorectal Cancer Liver Metastasis Treatment Model in Rats.
Animals
Antineoplastic Agents
/ adverse effects
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Colorectal Neoplasms
/ pathology
Diet
/ methods
Disease Models, Animal
Fluorouracil
/ adverse effects
Glycine
/ administration & dosage
Heart Injuries
/ chemically induced
Leucovorin
/ adverse effects
Liver Neoplasms
/ drug therapy
Male
Organoplatinum Compounds
/ adverse effects
Rats
FOLFOX
cardiotoxicity
colorectal cancer
glycine
Journal
Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595
Informations de publication
Date de publication:
28 Aug 2020
28 Aug 2020
Historique:
received:
08
06
2020
revised:
23
08
2020
accepted:
26
08
2020
entrez:
3
9
2020
pubmed:
3
9
2020
medline:
30
3
2021
Statut:
epublish
Résumé
FOLFOX chemotherapy (CTx) is used for the treatment of colorectal liver metastasis (CRLM). Side effects include rare cardiotoxicity, which may limit the application of FOLFOX. Currently, there is no effective strategy to prevent FOLFOX-induced cardiotoxicity. Glycine has been shown to protect livers from CTx-induced injury and oxidative stress, and it reduces platelet aggregation and improves microperfusion. This study tested the hypothesis of glycine being cardioprotective in a rat model of FOLFOX in combination with CRLM. The effect of glycine was tested in vitro on human cardiac myocytes (HCMs). To test glycine in vivo Wag/Rij rats with induced CRLM were treated with FOLFOX ±5% dietary glycine. Left ventricle ejection fraction (LVEF), myocardial fibrosis, and apoptosis, also heart fatty acid binding protein (h-FABP) and brain natriuretic peptide levels were monitored. PCR analysis for Collagen type I, II, and brain natriuretic peptide (BNP) in the heart muscle was performed. In vitro glycine had no effect on HCM cell viability. Treatment with FOLFOX resulted in a significant increase of h-FABP levels, increased myocardial fibrosis, and apoptosis as well as increased expression of type I Collagen. Furthermore, FOLFOX caused a decrease of LVEF by 10% ( Data presented here demonstrate for the first time that dietary glycine protects the heart against FOLFOX-induced injury during treatment for CRLM.
Identifiants
pubmed: 32872376
pii: nu12092634
doi: 10.3390/nu12092634
pmc: PMC7551625
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Organoplatinum Compounds
0
Leucovorin
Q573I9DVLP
Glycine
TE7660XO1C
Fluorouracil
U3P01618RT
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
PLoS One. 2015 Feb 11;10(2):e0115686
pubmed: 25671635
Heart Lung Circ. 2019 Oct;28(10):1598-1605
pubmed: 30205930
Ther Adv Med Oncol. 2018 Jun 18;10:1758835918780140
pubmed: 29977352
World J Gastroenterol. 2014 Aug 14;20(30):10316-30
pubmed: 25132748
Cancer Res. 1993 Jul 1;53(13):3028-33
pubmed: 8391384
Angiology. 2017 Jan;68(1):52-58
pubmed: 26980771
Br J Anaesth. 1999 Feb;82(2):250-4
pubmed: 10365003
J Clin Oncol. 2010 Dec 20;28(36):5280-6
pubmed: 21079148
Cancer Chemother Pharmacol. 2012 Jan;69(1):57-64
pubmed: 21603868
BMJ Case Rep. 2016 Jun 01;2016:
pubmed: 27251602
BMJ Case Rep. 2015 May 02;2015:
pubmed: 25935919
Amino Acids. 2011 Apr;40(4):1139-50
pubmed: 20852907
Drug Metab Dispos. 1992 Jan-Feb;20(1):113-9
pubmed: 1346985
Clin Sci (Lond). 2014 Jan 1;126(1):19-29
pubmed: 23742196
J Nutr. 2014 Oct;144(10):1540-8
pubmed: 25122646
BMC Surg. 2005 Aug 17;5:18
pubmed: 16105183
Life Sci. 2016 Jul 15;157:145-151
pubmed: 27297631
Pol J Pharmacol. 2004 Jan-Feb;56(1):121-8
pubmed: 15047986
J Clin Oncol. 1992 Nov;10(11):1795-801
pubmed: 1403060
Curr Opin Clin Nutr Metab Care. 2003 Mar;6(2):229-40
pubmed: 12589194
Br J Cancer. 1998;77(1):79-86
pubmed: 9459149
Am J Physiol. 1996 Feb;270(2 Pt 1):G332-8
pubmed: 8779976
Urology. 1995 Dec;46(6):821-4
pubmed: 7502423
Adv Drug Deliv Rev. 2019 Jun;146:77-82
pubmed: 31158407
Case Rep Oncol Med. 2014;2014:819396
pubmed: 25530895
Acta Pharmacol Sin. 2018 Jul;39(7):1155-1163
pubmed: 29770799
Tumori. 1982 Dec 31;68(6):505-10
pubmed: 7168016
Dalton Trans. 2018 May 15;47(19):6645-6653
pubmed: 29632935
Crit Rev Oncol Hematol. 2018 Apr;124:1-10
pubmed: 29548480
Carcinogenesis. 1999 May;20(5):793-8
pubmed: 10334195
Anticancer Drugs. 2009 Jan;20(1):79-80
pubmed: 19353811
J Clin Oncol. 1989 Apr;7(4):509-14
pubmed: 2466960
Clin Colorectal Cancer. 2006 Sep;6(3):202-7
pubmed: 17026789
Neoplasma. 1998;45(2):81-2
pubmed: 9687887
Amino Acids. 2013 Mar;44(3):925-31
pubmed: 23135224
Am J Psychiatry. 2000 May;157(5):826-8
pubmed: 10784481
Cardiovasc Revasc Med. 2013 Jan-Feb;14(1):57-61
pubmed: 23218901
Am J Physiol Gastrointest Liver Physiol. 2001 Jul;281(1):G200-7
pubmed: 11408273
Acta Anaesthesiol Scand. 2006 Feb;50(2):261-2; author reply 262
pubmed: 16430558
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2014 Dec;158(4):511-7
pubmed: 24457832
J Exp Clin Cancer Res. 2012 Jul 19;31:60
pubmed: 22812382
Curr Drug Metab. 2015;17(1):75-90
pubmed: 26526839
J Transl Med. 2013 Oct 02;11:244
pubmed: 24088575
Int J Biol Sci. 2019 Jun 4;15(8):1582-1590
pubmed: 31360101
Eur J Cancer. 2017 May;76:93-99
pubmed: 28286287
Sci Rep. 2019 Sep 10;9(1):12982
pubmed: 31506484
Int J Colorectal Dis. 2018 Sep;33(9):1241-1249
pubmed: 29931408
Amino Acids. 2016 Nov;48(11):2549-2558
pubmed: 27351202
BMJ Case Rep. 2019 Sep 12;12(9):
pubmed: 31519717
Am J Cardiol. 2010 Jan 1;105(1):1-9
pubmed: 20102882
Arch Pharm Res. 2017 Jul;40(7):875-883
pubmed: 28315259
Toxicol Lett. 2014 Jun 16;227(3):151-6
pubmed: 24704391
Eur J Pharmacol. 2017 Sep 15;811:125-128
pubmed: 28599874
J Am Coll Cardiol. 2009 Jun 16;53(24):2231-47
pubmed: 19520246
Nat Clin Pract Oncol. 2006 Feb;3(2):76-7
pubmed: 16462844
J Cardiovasc Med (Hagerstown). 2016 May;17 Suppl 1:S12-8
pubmed: 27183520
Physiol Res. 2012;61(4):419-23
pubmed: 22670699
Nutr Cancer. 1999;34(1):49-55
pubmed: 10453441
Int J Radiat Biol. 2014 Apr;90(4):284-90
pubmed: 24467328